Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis

BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) remains a common and highly morbid infection for immunocompromised patients. Trimethoprim-sulfamethoxazole (TMP-SMX) is the antimicrobial treatment of choice. However, treatment with TMP-SMX can lead to significant dose-dependent renal and hematolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler-Laporte, Guillaume, Smyth, Elizabeth, Amar-Zifkin, Alexandre, Cheng, Matthew P, McDonald, Emily G, Lee, Todd C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200085/
https://www.ncbi.nlm.nih.gov/pubmed/32391402
http://dx.doi.org/10.1093/ofid/ofaa112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200085/
https://www.ncbi.nlm.nih.gov/pubmed/32391402
http://dx.doi.org/10.1093/ofid/ofaa112

Ejemplares similares